Last updated on September 2019

A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults with Attention-deficit/Hyperactivity Disorder (Trial 405-201-00014)

Brief description of study

Centanafadine is being studied as a possible treatment for Attention-deficit/ Hyperactivity Disorder (ADHD).


Clinical Study Identifier: TX216179

Find a site near you

Start Over

Pharmacology Research Institute, Encino

6345 Balboa Blvd., Building III, Suite 363 Encino, CA United States
  Connect »